Galmed Pharmaceuticals Ltd. - Ordinary Shares, NIS 1.80 par value per share (GLMD)

Historical Holders from Q3 2024 to Q3 2025

Symbol
GLMD on Nasdaq
Type / Class
Equity / Ordinary Shares, NIS 1.80 par value per share
Shares outstanding
5,591,387
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
72,824
Holdings value
$102,011
% of all portfolios
0%
Number of holders
13
Number of buys
3
Number of sells
7
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Galmed Pharmaceuticals Ltd. - Ordinary Shares, NIS 1.80 par value per share (GLMD) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
CVI Investments, Inc. 3.1% -57% $346,666 173,333 0% CVI Investments, Inc. 30 Sep 2025
Baharaff Allen 2.6% $60,455 44,128 Allen Baharaff 31 Dec 2024
As of 30 Sep 2025 Galmed Pharmaceuticals Ltd. - Ordinary Shares, NIS 1.80 par value per share (GLMD) has 13 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 72,824 shares of 5,591,387 outstanding shares and own 1.3% of the company stock as of 30 Sep 2025.

Top 17 institutional shareholders of Galmed Pharmaceuticals Ltd. - Ordinary Shares, NIS 1.80 par value per share (GLMD) own 1.3% of the company based on 13F filings as of 30 Sep 2025

Filer Ownership Holdings Value Nb Shares Share Change %
CITADEL ADVISORS LLC 0.9% $71,194 50,492
TWO SIGMA INVESTMENTS, LP 0.38% $29,256 21,200
UBS Group AG 0.02% $1,329 963 -86%
MORGAN STANLEY 0% $135 98 -100%
Wealthspire Advisors, LLC 0% $29 21
SBI Securities Co., Ltd. 0% $22 16 -99%
Federation des caisses Desjardins du Quebec 0% $19 14 0%
WELLS FARGO & COMPANY/MN 0% $12 9 0%
OSAIC HOLDINGS, INC. 0% $6 5 0%
TD Waterhouse Canada Inc. 0% $3 2 0%
Allworth Financial LP 0% $3 2 0%
Dogwood Wealth Management LLC 0% $1 1 0%
ELEVATION WEALTH PARTNERS, LLC 0% $2 1 0%
Schonfeld Strategic Advisors LLC 0% $0 0 -100%
Cambridge Investment Research Advisors, Inc. 0% $0 0 -100%
Physician Wealth Advisors, Inc. 0% $0 0 -100%
RAYMOND JAMES FINANCIAL INC 0% $0 0 -100%

Institutional Holders of Galmed Pharmaceuticals Ltd. - Ordinary Shares, NIS 1.80 par value per share (GLMD) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q3 72,824 $102,011 -$18,462 $1.38 13
2025 Q2 75,987 $140,174 +$46,243 $1.86 14
2025 Q1 55,876 $80,439 +$15,875 $1.44 12
2024 Q4 44,767 $142,806 +$124,943 $3.19 11
2024 Q3 5,585 $38,313 +$38,306 $6.86 9